Protective Effects of Huangqi Shengmai Yin on Type 1 Diabetes-Induced Cardiomyopathy by Improving Myocardial Lipid Metabolism

Abstract

Diabetic cardiomyopathy (DCM) is one of the many complications of diabetes. DCM leads to cardiac insufficiency and myocardial remodeling and is the main cause of death in diabetic patients. Abnormal lipid metabolism plays an important role in the occurrence and development of DCM. Huangqi Shengmai Yin (HSY) has previously been shown to alleviate signs of heart disease. Here, we investigated whether HSY could improve cardiomyopathy caused by type 1 diabetes mellitus (T1DM) and improve abnormal lipid metabolism in the diabetic heart. Streptozotocin (STZ) was used to establish the T1DM mouse model, and T1DM mice were subsequently treated with HSY for eight weeks. The changes in the cardiac conduction system, histopathology, blood myocardial injury indices, and lipid content and expression of proteins related to lipid metabolism were evaluated. Our results showed that HSY could improve electrocardiogram; decrease the serum levels of CK-MB, LDH, and BNP; alleviate histopathological changes in cardiac tissue; and decrease myocardial lipid content in T1DM mice. These results indicate that HSY has a protective effect against T1DM-induced myocardial injury in mice and that this effect may be related to the improvement in myocardial lipid metabolism.

Fucoxanthin ameliorated myocardial fibrosis in STZ-induced diabetic rats and cell hypertrophy in HG-induced H9c2 cells by alleviating oxidative stress and restoring mitophagy

“…39 The leakage of CK, CK-MB and LDH into the serum indicates myocardial damage. 40,41 Then we detected the leakage of myocardial damage indicators CK, CK-MB, and LDH into the serum, and found that FX reversed the increase of CK, CK-MB and LDH in STZinduced diabetic rats, which indicates that FX can improve heart injury. STZ-induced diabetic rats after 8 weeks were shown to have different degrees of abnormality in left ventricular diastolic and systolic functions.…”

Molecular mechanisms of metabolic dysregulation in diabetic cardiomyopathy

“…Diabetic heart lipid metabolism is impacted due to changes in the expression of transporters involved in FA uptake (34), alterations in the PPAR signaling pathway during FA oxidation (35), accumulation of lipotoxicity, and activation of the MAPK signaling pathway (36). Lipid metabolism alterations in type 2 diabetes mellitus (T2DM) have been widely reported, and notably, lipid accumulation in type 1 diabetes mellitus (T1DM) has also been reported by relevant studies (37)(38)(39).…”

Fatty acid metabolism disorders and potential therapeutic traditional Chinese medicines in cardiovascular diseases

“…A recent study has reported that HSY could effectively inhibit the development of DCM in diabetic mice model. It was observed that HSY alleviated cardiac injury, and improved heart rate, while reduced QT interval and QRS complex by repairing unnormal myocardial lipid metabolism through increasing the expression of PPAR‐α, p‐AMPKα, SIRT1, PGC‐1α, and CPT‐1, and decreasing the activity of CD36 (Cao et al, 2021). The results indicated HSY alleviated DCM by promoting fatty acid oxidation while reducing fatty acid uptake.…”